Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: j bell who wrote (20)	6/26/1997 5:17:00 PM
From: Heat Shock	of 236

I was given a document written by a Canadian full-service investment company. They rated Stressgen a buy. Highlights follow: 1. early lead in the fast-growing field of stress protein biology 2. pre-clinical drug candidate application ---------------------------------- unigen vaccine meningitis pneumonia oncocine melanoma oncocine with antigen conjugate melanoma 3. good target therapeutic areas with US 1995 sales - cancer 2.2 billion - infectious disease 7 billion 4. Several big pharma companies are conducting stress protein research. [Anyone know who? what?] 5. Competition. Yikes. Antigenics- private US company, early preclinical. [Anyone know more about these guys?] 6. Stressgen's technology platform, proprietary position, and management team make it one of the more attractive early stage companies 7. expect major publication this quarter in infectious disease

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next